Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(-)-kurarinone
non-competitive inhibitor
-
(10Z,13Z)-nonadecadienoic acid
-
32% inhibition at 0.02 mM
(11Z,14Z)-eicosadienoic acid
-
42% inhibition at 0.02 mM
(11Z,14Z,17Z)-eisosatrienoic acid
-
19% inhibition at 0.02 mM
(12Z,15Z)-heneicosadienoic acid
-
39% inhibition at 0.02 mM
(13Z,16Z)-docosadienoic acid
-
39% inhibition at 0.02 mM
(13Z,16Z,19Z)-docosatrienoic acid
-
52% inhibition at 0.02 mM
(1R,2S)-2-([[6-(trifluoromethyl)-1H-indazol-4-yl]amino]methyl)cyclohexan-1-ol
-
-
(1R,2S)-2-[[(5-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(5-bromo-1H-indazol-7-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(5-chloro-1H-indazol-7-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexyl acetate
-
-
(1R,2S)-2-[[(6-chloro-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1R,2S)-2-[[(6-methyl-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(1S,2R)-2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
(2,4-dichlorophenyl)methanethiol
-
-
(2-chlorophenyl)methanethiol
-
-
(2E)-3-(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)prop-2-enoic acid
-
-
(2S)-2'-methoxy kurarinone
non-competitive inhibitor
-
(3,4-dichlorophenyl)methanethiol
-
-
(3-hydroxyphenyl)(phenyl)methanone
-
(3R,4S and 3S,4R)-3-bromo-4-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-3-hydroxy-2,2-dimethyl-4-morpholino-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-3-hydroxy-4-methoxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-4-(allylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-4-(benzylthio)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3R,4S and 3S,4R)-4-(butylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-3,4-dihydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
alpha-lapachone
(3S,4S and 3R,4R)-3-hydroxy-2,2-dimethyl-4-morpholino-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-3-hydroxy-4-methoxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-4-(allylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-4-(benzyloxy)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S and 3R,4R)-4-(benzylthio)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S)-4-(benzylamino)-3,9-dihydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(3S,4S)-4-(butylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
(4-chlorophenyl)methanethiol
-
-
(4-chlorophenyl)methanol
-
-
(4-fluorophenyl)methanethiol
-
-
(4-methoxyphenyl)methanethiol
-
-
(4-methylphenyl)methanethiol
-
-
(4E,4'E)-4,4'-bis(isopropylimino)-2,2'-binaphthyl-1,1'-(4H,4'H)-dione
-
(4E,4'E)-4,4'-bis(pentan-3-ylimino)-2,2'-binaphthyl-1,1'-(4H,4'H)-dione
-
(4Z,7Z,10Z,13Z,16Z)-docosapentaenoic acid
-
48% inhibition at 0.02 mM
(4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid
-
35% inhibition at 0.02 mM
(5Z,8Z)-7,7-dimethyl-5,8-eicosadienoic acid
-
29% inhibition at 0.02 mM
(5Z,8Z)-eicosadienoic acid
-
42% inhibition at 0.02 mM
(5Z,8Z,11Z)-eisosatrienoic acid
-
45% inhibition at 0.02 mM
(5Z,8Z,11Z,14Z)-eicosatetraenoic acid
-
55% inhibition at 0.02 mM; 80% inhibition at 0.02 mM
(5Z,8Z,11Z,14Z,17Z)-eicosapentaenoic acid
-
19% inhibition at 0.02 mM
(7Z,10Z,13Z,16Z)-docosatetraenoic acid
-
42% inhibition at 0.02 mM
(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)boronic acid
-
-
(8Z,11Z,14Z)-eisosatrienoic acid
-
68% inhibition at 0.02 mM
(9E,11Z)-octadecadienoic acid
-
26% inhibition at 0.02 mM
(9E,12E)-octadecadienoic acid
-
23% inhibition at 0.02 mM
(9Z,12Z)-octadecadienoic acid
-
16% inhibition at 0.02 mM
(9Z,12Z,15Z)-octadecatrienoic acid
-
23% inhibition at 0.02 mM
(E)-4-(isopropylimino)-2-methylnaphthalen-1(4H)-one
-
(E)-6-fluoro-3-[2-(3-pyridyl)vinyl]-1H-indole
-
-
(R)-2-amino-N-(4-hydroxynaphth-1-yl)propanamide
-
(S)-2-amino-5-((R)-1-(carboxymethylamino)-3-(1,4-dihydroxy-3-methylnaphthalen-2-ylthio)-1-oxopropan-2-ylamino)-5-oxopentanoic acid
-
(S)-2-amino-5-((R)-1-(carboxymethylamino)-3-(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-ylthio)-1-oxopropan-2-ylamino)-5-oxopentanoic acid
-
(S)-2-amino-N-(4-hydroxynaphth-1-yl)propanamide
-
1,6,6-trimethyl-10,11-dioxo-2-(thiophen-3-yl)-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl propanoate
0.02 mM, 29.3% inhibition
-
1,6,6-trimethyl-10,11-dioxo-2-phenyl-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl propanoate
0.02 mM, 21.5% inhibition
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl 1,3-thiazole-2-carboxylate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl acetate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl benzoate
0.02 mM, 54.5% inhibition
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl cyclohexanecarboxylate
0.02 mM, 48.0% inhibition
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl cyclopropanecarboxylate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl furan-3-carboxylate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl hydroxyacetate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl propanoate
-
-
1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl thiophene-2-carboxylate
0.02 mM, 60.4% inhibition
-
1,6,6-trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione
0.02 mM, 23.1% inhibition
1,6,6-trimethyl-6,7-dihydrophenanthro[1,2-b]furan-10,11-dione
0.02 mM, 61.2% inhibition
-
1,6,6-trimethylphenanthro[1,2-b]furan-7,10,11(6H)-trione
-
-
1,6,6-trimethylphenanthro[1,2-b]furan-9,10,11(6H)-trione
0.02 mM, 52.7% inhibition
-
1-(1,3-benzothiazol-2-ylsulfanyl)-N,N-dimethylmethanamine
-
1-(2-hydroxy-4-methylphenyl)-3-(2-methoxyphenyl)propane-1,3-dione
-
-
1-(2-hydroxy-4-methylphenyl)-3-{2-[(propan-2-yl)oxy]phenyl}propane-1,3-dione
-
-
1-(2-methylbenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-bromobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-bromothiophen-2-yl)-2-(3-methyl-1,4-dihydronaphthalen-2-yl)ethan-1-one
most potent inhibitor capable of blocking both indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase (TDO2) activity, with the IC50 value for BT-549 cells at 0.00342 mM
-
1-(3-chlorobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-[(4-acetyl-1-piperazinyl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
1-(3-[(4-methyl-1-piperazinyl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-bromobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-bromophenyl)-2-[[5-(4-chlorophenyl)[1,3]thiazolo[2,3-c]-[1,2,4]triazol-3-yl]sulfanyl]ethanone
-
-
1-(4-chlorobenzyl)urea
-
-
1-(4-chlorophenyl)methanamine
-
-
1-(4-chlorophenyl)thiourea
-
-
1-(4-cyanophenyl)-3-(3-(cyclopropylethynyl)imidazo[2,1-b]thiazol-5-yl)thiourea
potent inhibitor. The basis for this high potency is a unique sulfur-aromatic interaction network formed by the thiourea moiety of the inhibitor with F163 and F226
-
1-(4-fluorobenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-methylbenzyl)-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-[(4-acetylpiperazin-1-yl)carbonyl]benzyl)-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
1-(4-[(4-methoxypiperidin-1-yl)carbonyl]benzyl)-1Hnaphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-(hydroxymethyl)-6,6-dimethylphenanthro[1,2-b]furan-7,10,11(6H)-trione
-
-
1-(hydroxymethyl)-6,6-dimethylphenanthro[1,2-b]furan-9,10,11(6H)-trione
0.02 mM, 68% inhibition
-
1-benzofuran-DL-tryptophan
-
1 mM, 43% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
1-benzothiophene-DL-tryptophan
-
1 mM, 16% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
1-benzyl-5-phenyl-1H-imidazole
-
1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol
1-hydroxy-5,6-dimethoxy-3-oxo-2-phenyl-3H-indol-1-ium
-
1-methyl tryptophan
a tryptophan analogue. Galanal does not decrease the IkappaB-alpha expression in LPS-stimulated THP-1 cells
1-oxo-2-phenyl-3H-1lambda5-indol-3-one
-
1-phenyl-2-(phenylsulfanyl)hydrazine
-
1-[(3-methylphenyl)methyl]-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-[(4-chlorophenyl)methyl]-1H-naphtho[2,3-d][1,2,3]triazole-4,9-dione
-
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-3-carboxylic acid
-
-
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-4-carboxylic acid
-
-
1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]proline
-
-
1-[2-(4-chlorophenyl)ethyl]thiourea
-
-
1-[3-(4-morpholinylcarbonyl)benzyl]-1H-naphtho[2,3-d]-[1,2,3]triazole-4,9-dione
-
1-[4-(morpholin-4-ylcarbonyl)benzyl]-1H-naphtho[2,3-d]-[1,2,3]triazole-4,9-dione
-
1-[4-[(4-methylpiperazin-1-yl)carbonyl]benzyl]-1H-naphtho-[2,3-d][1,2,3]triazole-4,9-dione
-
1-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-3-(4-methylphenyl)imidazolidin-2-one
-
-
15-deoxy-DELTA12,14-prostaglandin
-
-
1H-phenanthro[9,10-d]imidazole
-
2,2-dimethyl-1a,9b-dihydro-2H-benzo[g]oxireno[c]chromene-4,9-dione
-
2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
dehydro-alpha-lapachone
2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
2,2-dimethyl-3,4-epoxy-2H-naphtho[2,3-b]pyran-5,10-dione
-
2,3-dichloro-1,4-naphthoquinone
-
2,4-dichlorobenzyl carbamimidothioate hydrobromide
-
-
2-(1H-imidazol-4-yl)benzene-1,3-diol
-
2-(1H-imidazol-4-yl)benzenethiol
-
2-(1H-imidazol-4-yl)phenol
2-(1H-phenanthro[9,10-d]imidazol-2-yl)phenol
-
2-(1H-pyrazol-3-yl)phenol
-
2-(2-chlorophenyl)ethyl carbamimidothioate hydrobromide
-
-
2-(2-fluorophenyl)-1H-phenanthro[9,10-d]imidazole
-
2-(2-methylphenyl)-1-oxo-3H-1lambda5-indol-3-one
-
2-(2-methylphenyl)-1H-phenanthro[9,10-d]imidazole
-
2-(2-sulfanylidene-2,3-dihydro-1,3-thiazol-4-yl)benzoic acid
0.1 mM, 8% inhibition
-
2-(3-chlorophenyl)ethyl carbamimidothioate hydrobromide
-
-
2-(4-chlorophenyl)ethanamine
-
-
2-(4-chlorophenyl)ethyl carbamimidothioate hydrobromide
-
-
2-(4-methoxyphenyl)-1-oxo-3H-1lambda5-indol-3-one
-
2-(4-methoxyphenyl)-3H-indol-3-one
-
2-(4-methoxyphenyl)-3H-indole
-
2-(4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]-triazol-1-yl)methyl]phenyl)-N,N-diethylacetamide
-
2-([5-(3-methoxyphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)-N-(5-methyl-1,3-thiazol-2-yl)acetamide
poor inhibitor; poor inhibitor
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (2-chlorophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (2-hydroxyphenyl)acetate
0.001 mM, 73% inhibition
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (2-nitrophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3,4-dihydroxyphenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3-chlorophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3-cyanophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3-hydroxyphenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (3-nitrophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-chlorophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-cyanophenyl)acetate
0.001 mM, 69% inhibition
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-hydroxyphenyl)acetate
0.001 mM, 89% inhibition
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl (4-nitrophenyl)acetate
-
-
2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl phenylacetate
0.001 mM, 72% inhibition
-
2-amino-3-hydroxy-N-(4-hydroxynaphthalen-1-yl)propanamide
-
2-amino-N-(4-hydroxynaphth-1-yl)acetamide
-
2-bromo-4-phenyl-1,3-thiazole
0.1 mM, 12% inhibition
-
2-bromo-L-tryptophan
-
1 mM, 11% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
2-chloro-4-phenyl-1,3-thiazole
0.1 mM, 0.5% inhibition
-
2-chloro-L-tryptophan
-
1 mM, 20% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
2-chloro-N-[[(4-chlorophenyl)sulfanyl]methyl]aniline
-
2-chlorobenzyl carbamimidothioate hydrochloride
-
-
2-Hydroxy-1,4-naphthoquinone
-
2-hydroxy-L-tryptophan
-
1 mM, 30% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
2-mercaptobenzothiazole
-
2-methoxy-1,4-naphthoquinone
-
2-methyl-1,4-naphthoquinone
-
2-methylnaphthalene-1,4-dione
-
2-phenyl-3H-indol-3-imine
-
2-phenyl-3H-indol-3-one
-
2-[(6-bromo-1H-indazol-4-yl)amino]-1-(3-chlorophenyl)ethan-1-ol
-
-
2-[(6-bromo-1H-indazol-4-yl)amino]-1-(4-hydroxyphenyl)ethan-1-one
-
-
2-[(6-bromo-1H-indazol-4-yl)amino]-2-(3-chlorophenyl)ethan-1-ol
-
-
2-[(6-bromo-1H-indazol-4-yl)amino]-2-phenylethan-1-ol
-
-
2-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoic acid
-
-
2-[[(2,4-dichlorophenyl)methyl]sulfanyl]-6-methylpyrimidin-4(5H)-one
-
2-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexan-1-ol
-
-
2-[[5-cyano-4-(3-methoxyphenyl)-6-oxo-1,6-dihydropyrimidin-2-yl]sulfanyl]-N-[5-(propan-2-yl)thiophen-2-yl]butanamide
0.01 mM, 24.4% inhibition
-
3'-[[(2-chlorophenyl)carbamoyl]amino]-4-methoxy-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
3'-[[(2-fluorophenyl)carbamoyl]amino]-4-methoxy-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[(2-methylpropyl)(propan-2-yl)amino][1,1'-biphenyl]-2-carboxylic acid
-
-
3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[(4aS,8aS)-octahydroquinolin-1(2H)-yl][1,1'-biphenyl]-2-carboxylic acid
-
-
3,4-dichlorobenzyl carbamimidothioate hydrochloride
-
-
3-(1H-1,2,3-triazol-5-yl)pyridine
3-(1H-imidazol-4-yl)benzaldehyde
-
3-(1H-imidazol-4-yl)benzenethiol
-
3-(1H-imidazol-4-yl)benzonitrile
-
3-(1H-imidazol-4-yl)phenol
-
3-(1H-phenanthro[9,10-d]imidazol-2-yl)phenol
-
3-(2-aminoethyl)-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 74.88% inhibition
-
3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazole
-
-
3-(4H-imidazol-4-yl)benzenethiol
-
3-chlorobenzyl carbamimidothioate hydrochloride
-
-
3-hydroxy-2,2-dimethyl-4-(morpholin-4-yl)-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
3-hydroxy-4-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
3-hydroxyanthranilic acid
-
-
3-indoleethanol
-
lowers Km value for D-tryptophan by 25% at pH 7, enhances Vmax by 40-60%
3-methyl-8-(4,4,4-trifluorobutoxy)-5H-indeno[1,2-c]pyridazin-5-one
-
31% inhibition at 0.025 mM
3-methyl-8-[(3-methylbenzyl)oxy]-5H-indeno[1,2-c]pyridazin-5-one
-
66% inhibition at 0.025 mM
3-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]-N,N-diethylbenzamide
-
3-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]benzoic acid
-
3-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoic acid
-
-
3-[2-(cyclohexylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 64.95% inhibition
-
3-[2-(diethylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 64.21% inhibition
-
3-[2-(dimethylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 71.26% inhibition
-
3-[2-(ethylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 81.67% inhibition
-
3-[2-(propylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 79.17% inhibition
-
3-[2-(tert-butylamino)ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 79.45% inhibition
-
3-[2-[(2-phenylethyl)amino]ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 68.26% inhibition
-
3-[2-[(propan-2-yl)amino]ethyl]-5-(pyridin-3-yl)-1H-indole-4,7-dione
0.01 mM, 63.75% inhibition
-
3-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]propanoic acid
EC50 is 183 nm
4'-(2,3-dimethylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-3'-([[4-(2-hydroxypropan-2-yl)phenyl]carbamoyl]amino)-4-methoxy[1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-3'-[[(4-chlorophenyl)carbamoyl]amino]-4-methoxy[1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-3'-[[(4-cyanophenyl)carbamoyl]amino]-4-methoxy[1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-4-methoxy-3'-[[(4-methoxyphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-chlorophenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-ethylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylanilino)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-2-fluoro-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-4-chloro-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-4-ethoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(2-tert-butylphenoxy)-5-chloro-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(3-tert-butylphenoxy)-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-(cyclohexylamino)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-(dibutylamino)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-[(2,3-dihydro-1H-inden-4-yl)oxy]-4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-3-carboxylic acid
-
-
4'-[bis(2-methylpropyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-[bis(2-methylpropyl)amino]-N-(methanesulfonyl)-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxamide
-
-
4'-[bis(cyclopropylmethyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-[cyclohexyl(methyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4'-[cyclopentyl(ethyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-carboxylic acid
-
-
4-(1H-1,2,3-triazol-5-yl)pyridine
-
4-(1H-imidazol-4-yl)phenol
-
4-(1H-phenanthro[9,10-d]imidazol-2-yl)phenol
-
4-(2,6-dimethoxyphenyl)-1H-imidazole
-
4-(2-(diethylamino)ethylamino)-1-naphthol
-
4-(2-(methylthio)phenyl)-1H-imidazole
-
4-(2-fluorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 77% inhibition
-
4-(2-fluorophenyl)-1H-imidazole
-
4-(2-hydroxyethoxy)-1-naphthol
-
4-(2-methoxyphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 53% inhibition
-
4-(2-sulfanylidene-2,3-dihydro-1,3-thiazol-4-yl)benzonitrile
0.1 mM, 8% inhibition
-
4-(3-(methylthio)phenyl)-1H-imidazole
-
4-(3-bromophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 81% inhibition
-
4-(3-chlorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 40% inhibition
-
4-(3-chlorophenyl)-imidazole
-
-
4-(3-fluorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 28% inhibition
-
4-(3-fluorophenyl)-1H-imidazole
-
4-(4-(methylthio)phenyl)-1H-imidazole
-
4-(4-bromophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 100% inhibition
-
4-(4-chlorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 95% inhibition
-
4-(4-fluorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 72% inhibition
-
4-(4-fluorophenyl)-1H-imidazole
-
4-(4-methoxyphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 68% inhibition
-
4-(4-methylbenzene-1-sulfinyl)-7-nitro-2,1,3-benzoxadiazole
-
4-(4-methylphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 90% inhibition
-
4-(benzylamino)-1-naphthol
-
4-(benzylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
4-(butylamino)-3-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
4-(cyclohexylamino)-1-naphthol
-
4-(dimethylamino)naphthalen-1-ol
-
4-(ethylamino)-1-naphthol
-
4-(isobutylamino)-1-naphthol
-
4-(isopropylamino)-1-naphthol
-
4-(methanesulfonyl)-N'-(3-methylphenyl)benzene-1-sulfonohydrazide
EC5 is 7846 nm
4-(methylamino)naphthalen-1-ol
-
4-(pent-3-ylamino)-1-naphthol
-
4-(phenylcarbonyl)benzyl carbamimidothioate hydrobromide
-
-
4-(propan-2-yl)benzyl carbamimidothioate hydrobromide
-
-
4-(propylamino)-1-naphthol
-
4-(pyridin-3-yl)-1,3-thiazole-2(3H)-thione
0.1 mM, 48% inhibition
-
4-(pyridin-4-yl)-1,3-thiazole-2(3H)-thione
0.1 mM, 21% inhibition
-
4-(tert-butylamino)naphthalen-1-ol
-
4-(thiophen-2-yl)-1H-imidazole
-
4-(trifluoromethyl)benzyl carbamimidothioate hydrochloride
-
-
4-([[(1S,2R)-2-hydroxycyclohexyl]methyl]amino)-1H-indazole-6-carboxylic acid
-
-
4-amino-1,2,3-oxadiazole-3-carboximidamide
-
-
4-amino-1,2,5-oxadiazole-3-carboximidamide
-
competitive
4-amino-N'-hydroxy-N-(3-isopropylphenyl)-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N'-hydroxy-N-(3-methoxyphenyl)-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N'-hydroxy-N-(3-methylphenyl)-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N'-hydroxy-N-phenyl-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(2-chlorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-bromophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
4-amino-N-(3-chlorophenyl)-1,2,5-oxadiazole-3-carbohydrazonamide
-
-
4-amino-N-(3-chlorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-ethylphenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-tert-butylphenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(4-chlorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-benzyl-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-bromo-5-(4-methylphenyl)-1H-1,2,3-triazole
-
-
4-bromo-N'-(4-bromophenyl)benzene-1-sulfonohydrazide
EC50 is 374 nm
4-bromobenzyl carbamimidothioate hydrobromide
-
-
4-chloro-2-(1H-1,2,3-triazol-4-yl)phenol
i.e. MMG-0358
-
4-chlorobenzenesulfonic acid
-
-
4-chlorobenzyl carbamimidothioate hydrochloride
-
-
4-chlorobenzyl N,N'-dimethylcarbamimidothioate - 1-chlorotetraoxidane (1:1)
-
-
4-chlorophenyl-1,2,3-triazol-4-amine
-
-
4-cyano-N'-(3-methylphenyl)benzene-1-sulfonohydrazide
EC50 is 3404 nm
4-cyanobenzyl carbamimidothioate hydrobromide
-
-
4-ethylbenzyl carbamimidothioate hydrochloride
-
-
4-fluoro-2-(1H-pyrazol-3-yl)phenol
-
4-fluorobenzyl carbamimidothioate hydrochloride
-
-
4-iodo-5-phenyl-1H-1,2,3-triazole
-
-
4-methoxy-1-naphthylamine
-
4-methoxy-3'-[(phenylcarbamoyl)amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(2-methylphenyl)carbamoyl]amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(3-methylphenyl)carbamoyl]amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-(2-propylphenoxy)[1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[(5,6,7,8-tetrahydronaphthalen-1-yl)oxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[2-(propan-2-yl)phenoxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxy-3'-[[(4-methylphenyl)carbamoyl]amino]-4'-[2-methyl-3-[(prop-2-yn-1-yl)oxy]phenoxy][1,1'-biphenyl]-3-carboxylic acid
-
-
4-methoxybenzyl carbamimidothioate hydrochloride
-
-
4-methyl-DL-tryptophan
-
1 mM, 26% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
4-methylbenzyl carbamimidothioate hydrochloride
-
-
4-nitro-2,1,3-benzothiadiazole
-
4-nitro-5-(4-nitrophenyl)-1H-1,2,3-triazole
-
-
4-nitro-7-[(1-oxo-1lambda5--pyridin-2-yl)sulfanyl]-2,1,3-benzoxadiazole
-
4-nitrobenzyl carbamimidothioate hydrochloride
-
-
4-phenyl-1,3-thiazol-2(3H)-one
0.1 mM, 15% inhibition
-
4-phenyl-1,3-thiazol-2-amine
4-phenyl-1,3-thiazole-2(3H)-thione
0.1 mM, 76% inhibition
-
4-phenyl-1,3-thiazole-2-thiol
-
4-phenyl-imidazole
4-phenyl-imidazole coordinates transiently to the heme iron
4-tert-butylbenzyl carbamimidothioate hydrobromide
-
-
4-[(1Z)-2-[(6-bromo-1H-indazol-4-yl)amino]-N-hydroxyethanimidoyl]phenol
-
-
4-[(2,4-dichlorophenyl)sulfanyl]-7-nitro-2,1,3-benzoxadiazole
-
4-[(3-chlorophenyl)sulfanyl]-7-nitro-2,1,3-benzoxadiazole
-
4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]-N,N-diethylbenzamide
-
4-[(4,9-dioxo-4,9-dihydro-1H-naphtho[2,3-d][1,2,3]triazol-1-yl)methyl]benzoic acid
-
4-[(4-fluorophenyl)sulfanyl]-7-nitro-2,1,3-benzoxadiazole
-
4-[(4-methylphenyl)sulfanyl]-7-nitro-2,1,3-benzoxadiazole
-
4-[(carbamimidoylsulfanyl)methyl]benzoic acid hydrochloride
-
-
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzamide
-
-
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzene-1-sulfonamide
potent inhibitor with a moderate pharmacokinetic profile. 25% tumor growth inhibition and 30% reduction in tumor weight in a murine CT26 syngeneic model on day 18, with 100 mg/kg oral administration twice daily
-
4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoic acid
-
-
4-[2-(4-bromophenyl)hydrazinesulfonyl]benzoic acid
EC50 is 172 nm
4-[2-(methylsulfanyl)phenyl]-1H-imidazole
-
4-[3-(hydroxymethyl)phenyl]-1,3-thiazole-2(3H)-thione
0.1 mM, 16% inhibition
-
4-[3-(methylsulfanyl)phenyl]-1H-imidazole
-
4-[4-(trifluoromethyl)phenyl]-1,3-thiazole-2(3H)-thione
0.1 mM, 37% inhibition
-
4-[[(2,4-dichlorophenyl)methyl]sulfanyl]-6-methylpyrimidin-2(1H)-one
-
4-[[(2,4-dichlorophenyl)methyl]sulfanyl]pyrimidin-2(1H)-one
-
4-[[(6-bromo-1H-indazol-4-yl)amino]methyl]phenol
-
-
5-(2-bromophenyl)-1H-1,2,3-triazole
-
-
5-(2-chlorophenyl)-1H-1,2,3-triazole
-
-
5-(2-fluorophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 29% inhibition
-
5-(2-methoxyphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 12% inhibition
-
5-(2-methoxyphenyl)-1H-1,2,3-triazole
-
-
5-(3-bromophenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 48% inhibition
-
5-(4-bromophenyl)-1H-1,2,3-triazole
-
-
5-(4-chlorophenyl)-1H-1,2,3-triazole
-
-
5-(4-chlorophenyl)-3-[(2-methylpropyl)sulfanyl][1,3]thiazolo-[2,3-c][1,2,4]triazole
-
-
5-(4-fluorophenyl)-1H-1,2,3-triazole
-
-
5-(4-methoxyphenyl)-1H-1,2,3-triazole
-
-
5-(4-methylphenyl)-1,3-thiazole-2(3H)-thione
0.1 mM, 15% inhibition
-
5-(ethylamino)quinolin-8-ol
-
5-(isopropylamino)quinolin-8-ol
-
5-amino-8-hydroxyquinoline
-
5-benzyloxy-DL-tryptophan
-
1 mM, 2% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-bromo-DL-tryptophan
-
1 mM, 56% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-chloro-1,3-benzothiazole-2(3H)-thione
-
5-fluoro-DL-tryptophan
-
1 mM, 32% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-hydroxy-1,4-naphthoquinone
-
5-hydroxy-D-tryptophan
-
0.1 mM, 26% inhibition of cleavage of D-tryptophan, 29% inhibition of cleavage of L-tryptophan
5-hydroxyindole acetic acid
-
1 mM, 61.5% inhibition
5-hydroxytryptamine
-
1 mM, 82.3% inhibition
5-hydroxytryptophan
-
1 mM, 78.6% inhibition
5-methoxy-DL-tryptophan
-
1 mM, 35% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-methyl-DL-tryptophan
-
1 mM, 6% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-phenyl-1,3-thiazole-2(3H)-thione
0.1 mM, 16% inhibition
-
5-phenyl-1H-1,2,3-triazole
5-[(2E)-2-[(4-bromophenyl)methylidene]hydrazinyl]-1-(naphthalen-1-yl)tetrazolidine
0.01 mM, 54.3% inhibition
-
5-[[(2,4-dichlorophenyl)methyl]sulfanyl]-1H-1,2,4-triazole
-
6-(4-iodo-2-methylanilino)-2,1,3-benzoxadiazole-5-carboxylic acid
-
6-(4-iodo-2-methylanilino)-3-oxo-2,1,3lambda~5~-benzoxadiazole-5-carboxylic acid
-
6-bromo-1H-indazol-4-amine
-
-
6-bromo-N-(cyclohexylmethyl)-1H-indazol-4-amine
-
-
6-bromo-N-[(1,4-dioxaspiro[4.5]decan-6-yl)methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[(1R,2R)-2-hydroxycyclohexyl]-1H-indazole-4-carboxamide
-
-
6-bromo-N-[(pyridin-2-yl)methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[(pyrrolidin-3-yl)methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(1S,2R)-2-chlorocyclohexyl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(1S,2S)-2-chlorocyclohexyl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2R)-piperidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2R)-pyrrolidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2S)-piperidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-bromo-N-[[(2S)-pyrrolidin-2-yl]methyl]-1H-indazol-4-amine
-
-
6-fluoro-DL-tryptophan
-
1 mM, 54% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
6-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
6-hydroxy-2,2-dimethyl-3,4-dihydro-2H-benzo[g]chromene-5,10-dione
-
6-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
6-methyl-DL-tryptophan
-
1 mM, 20% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
6-nitro-D-tryptophan
-
1 mM, 7% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
6-nitro-L-tryptophan
-
1 mM, competitive inhibition, 52% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
7-amino-2-[(2E)-3-(2H-1,3-benzodioxol-5-yl)prop-2-enoyl]-4-bromocyclohepta-2,4,6-trien-1-one
0.01 mM, 21.4% inhibition
-
7-fluoro-4-(2-fluoro-4-iodoanilino)-2,1,3-benzoxadiazole-5-carboxylic acid
-
7-hydroxy-1,6,6-trimethyl-6,7-dihydrophenanthro[1,2-b]furan-10,11-dione
-
-
7-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
7-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
7-methyl-DL-tryptophan
-
1 mM, 36% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
7-nitro-N-phenyl-2,1,3-benzoxadiazol-4-amine
-
8-(4,4,4-trifluorobutoxy)-3-[3-(trifluoromethyl)phenyl]-5H-indeno[1,2-c]pyridazin-5-one
-
20% inhibition at 0.025 mM
8-(benzyloxy)-3-[3-(trifluoromethyl)phenyl]-5H-indeno[1,2-c]pyridazin-5-one
-
-
8-fluoro-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indolo[2,1-b]quinazoline-6,12-dione
-
-
8-fluoro-2-[(1H-1,2,3-triazol-1-yl)methyl]indolo[2,1-b]quinazoline-6,12-dione
-
-
8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazoline-2-carbaldehyde
-
-
8-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
8-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
8-methoxy-3-[3-(trifluoromethyl)phenyl]-5H-indeno[1,2-c]pyridazin-5-one
-
18% inhibition at 0.025 mM
8-[(3-chlorobenzyl)oxy]-3-methyl-5H-indeno[1,2-c]pyridazin-5-one
-
19% inhibition at 0.025 mM
9-hydroxy-1,6,6-trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione
-
-
9-hydroxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
alpha-caryopterone
9-methoxy-2,2-dimethyl-2H-benzo[g]chromene-5,10-dione
-
acetaminophen
-
no affect on holoenzyme, significant inhibition of apoenzyme, changes in brain serotonin levels due to inhibition of hepatic tryptophan 2,3-dioxygenase
alpha-methyl-DL-tryptophan
-
1 mM, 1% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
alpha-N-methyl-L-tryptophan
-
1 mM, 33% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
antisense oligonucleotide A06007H
+G*+A*+T*T*G*T*C*C*A*G*G*A*+G*+T*+T, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06008H
+C*+T*+C*A*A*C*T*C*T*T*T*C*+T*+C*+G, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06030H
+A*+G*+G*C*G*C*T*G*T*G*A*C*T*+T*+G*+T, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06043H
+C*+C*+A*G*A*C*T*C*T*A*T*G*A*G*+A*+T*+C, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06044H
+G*+A*+G*A*T*G*A*T*C*A*A*T*G*C*+T*+G*+A, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A06045H
+A*+G*+G*C*G*C*T*G*T*G*A*C*T*T*+G*+T*+G, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A07006H
+T*+G*+T*A*T*G*A*C*A*G*C*+C*+G*+T, (+) LNA-modified nucleotide, (*) PTO linkage
-
antisense oligonucleotide A07058H
+A*+T*+C*G*T*G*G*T*G*C*T*G*A*A*+C*+A*+A, (+) LNA-modified nucleotide, (*) PTO linkage
-
baicalein
-
uncompetitive reversible potent IDO-1 inhibitor
Bathocuproinesulfonate
-
competitive with respect to L-Trp and noncompetitive with respect to O2
benzyl carbamimidothioate hydrochloride
-
-
Berberine
-
uncompetitive reversible potent IDO-1 inhibitor
beta-Methyl-DL-tryptophan
-
1 mM, 7% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
Cd2+
-
0.5-1.0 mM, non-competitive
Cu2+
-
0.005 mM, 50% inhibition
DL-5-hydroxytryptophan
-
1 mM, 55% inhibition
DL-alpha-methyltryptophan
-
-
epigallocatechin gallate
-
-
ethyl (2E)-3-(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)prop-2-enoate
-
-
ethyl 1,6,6-trimethyl-10,11-dioxo-6,7,8,9,10,11-hexahydrophenanthro[1,2-b]furan-9-yl (2E)-but-2-enedioate
-
-
ethyl 1-(4-chlorophenyl)-1H-1,2,3-triazole-4-carboxylate
-
-
galanal
competitive inhibitor, IC50 value of 45 nM in the cell-based assay. galanal interfered with the transcriptional function of the nuclear factor-kappaB and the interferon-gamma signaling pathway. These effects of galanal are important for immune response. The inhibitory effect of galanal on IDO1 activity is stronger than that of 1-methyl tryptophan, a tryptophan analogue
gamma-glutamyl-S-(3-methyl-1,4-dioxo-1,4-dihydronaphthalen-2-yl)cysteinylglycine
-
hydroxylamine sulfate
-
0.1 mM causes 79% inhibition, 1 mM causes 94% inhibition
imidazole
-
negatively cooperative or competitive
imidodicarbonimidic diamide, N-methyl-N''-9-phenanthrenyl-, monohydrochloride
-
-
INCB024360
0.01 mM, 97.59% inhibition
-
indole-3-acetic acid
-
1 mM, 19% inhibition of cleavage of D-tryptophan, 27% inhibition of cleavage of L-tryptophan
indole-3-acrylic acid
-
competitive inhibitor
Indole-3-propionic acid
-
-
iodoacetic acid
-
1 mM, 12% inhibition of cleavage of D-tryptophan, 7% inhibition of cleavage of L-tryptophan
Jatrorrhizine
-
irreversible potent IDO-1 inhibitor
K3Fe(CN)6
-
1 mM, complete inhibition
kushenol E
non-competitive inhibitor, the inhibitor might be useful in the development of immunotherapeutic agents against cancers
kushenol F
non-competitive inhibitor
-
Kynurenic acid
-
0.1 mM, 57.2% inhibition. 1 mM, 99.4% inhibition
L-kynurenine
-
0.1 mM, 17.7% inhibition. 1 mM, 93.6% inhibition
L-tryptophan ethyl ester
-
1 mM, 7% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
L-tryptophan methyl ester
-
1 mM, 30% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
levo-1-methyl tryptophan
-
-
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-3-carboxylate
-
-
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]piperidine-4-carboxylate
-
-
methyl 1-[(8-fluoro-6,12-dioxo-6,12-dihydroindolo[2,1-b]quinazolin-2-yl)methyl]prolinate
-
-
methyl 2-methyl-5,10-dioxo-5,10-dihydro-2H-benzo[g]chromene-2-carboxylate
-
methyl 3-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]propanoate
EC50 is 465 nm
methyl 4-([[(1S,2R)-2-hydroxycyclohexyl]methyl]amino)-1H-indazole-6-carboxylate
-
-
methyl 4-[(carbamimidoylsulfanyl)methyl]benzenesulfinate hydrobromide
-
-
methyl 7-fluoro-4-(2-fluoro-4-iodoanilino)-2,1,3-benzoxadiazole-5-carboxylate
-
methyl N-(4-chlorophenyl)carbamimidothioate hydroiodide
-
-
methyl N-[2-(4-chlorophenyl)ethyl]carbamimidothioate hydroiodide
-
-
methyl thiohydantoin-Trp
-
methyl-thiohydantoin tryptophan
-
-
methyl-thiohydantoin-L-tryptophan
-
competitive inhibitor
methyl-thiohydantoin-tryptophan
-
limited selectivity towards indoleamine 2,3-dioxygenase
methylene blue
addition of methylene blue (0-0.1 mM) to NADPH-cytochrome P450 reductase-supported D-Trp incubations (with or without cytochrome b5) leads to concentration-dependent inhibition of IDO activity, addition of methylene blue (0-0.03 mM) to NADPH-cytochrome P450 reductase-supported L-Trp oxidation reactions results in a switch from substrate inhibition kinetics to Michaelis-Menten with increasing methylene blue concentration decreasing the affinity of IDO for L-Trp
methylthiohydantoin-DL-tryptophan
-
N'-(3-methylphenyl)-4-[[5-(trifluoromethyl)pyridin-2-yl]oxy]benzene-1-sulfonohydrazide
EC50 is 296 nm
N'-(4-bromophenyl)-4-cyanobenzene-1-sulfonohydrazide
EC50 is 134 nm
N'-(4-bromophenyl)-4-methoxybenzene-1-sulfonohydrazide
EC50 is 640 nm
N'-(4-bromophenyl)benzenesulfonohydrazide
EC50 is 128 nm
N'-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-N-methyl-N-(4-methylphenyl)urea
-
-
N,N-dimethyl-1-[(4-phenyl-1,3-thiazol-2-yl)sulfanyl]methanamine
-
N-(1,3-benzodioxol-5-yl)-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
a reversible inhibitor of IDO1. highly specific for IDO1 compared to IDO2, docking analysis with IDO1 and IDO2; a reversible inhibitor of IDO1. highly specific for IDO1 compared to IDO2, docking analysis with IDO1 and IDO2
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-1H-indole-2-carboxamide
-
-
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-4-bromo-1H-pyrrole-2-carboxamide
selective inhibitor of IDO1 against L-Trp dioxygenase (TDO) at 0.001 mM, yet when the concentration is increased up to 0.010 mM, an inhibition of TDO is observed to some extent
-
N-(3-((1H-benzo[d]imidazol-1-yl)methyl)benzyl)-4-cyanobenzamide
-
-
N-(3-bromo-4-fluorophenyl)-N'-hydroxy-4-[[2-(sulfamoylamino)ethyl]amino]-1,2,5-oxadiazole-3-carboximidamide
-
-
N-(4'-[bis(2-methylpropyl)amino]-3'-[[(4-methylphenyl)carbamoyl]amino][1,1'-biphenyl]-2-yl)-1,1,1-trifluoromethanesulfonamide
-
-
N-(4-bromophenyl)-7-nitro-2,1,3-benzoxadiazol-4-amine
-
N-(4-bromophenyl)-N'-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]urea
-
-
N-(4-chlorophenyl)-2H-1,2,3-triazol-4-amine
i.e. Vertex-AT
-
N-(4-hydroxy-1-naphthyl)ethane-1,2-diaminium chloride
-
N-(4-hydroxy-1-naphthyl)propane-1,3-diaminium chloride
-
N-(4-hydroxynaphthalen-1-yl)pyrrolidine-2-carboxamide
-
N-(4-methoxyphenyl)-7-nitro-2,1,3-benzoxadiazol-4-amine
-
N-(4-methylphenyl)-2,1,3-benzoxadiazol-4-amine
-
N-(4-methylphenyl)-7-nitro-2,1,3-benzoxadiazol-4-amine
-
N-(4-[2-[4-(trifluoromethyl)phenyl]hydrazinesulfonyl]phenyl)acetamide
EC50 is 181 nm
N-(4-[[(6-bromo-1H-indazol-4-yl)amino]methyl]cyclohexylidene)hydroxylamine
-
-
N-(phenyldisulfanyl)aniline
-
N-acetyl-L-tryptophan
-
1 mM, 7% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
n-butyl isocyanide
-
heme ligand which binds tightly to the ferrous enzyme
N-carbamoyl-2-([5-(4-methylphenyl)[1,3]thiazolo[2,3-c][1,2,4]triazol-3-yl]sulfanyl)acetamide
poor inhibitor; poor inhibitor
N-ethylmaleimide
-
1 mM, 58% inhibition of cleavage of D-tryptophan, 45% inhibition of cleavage of L-tryptophan
N-phenyl-p-phenylenediamine
-
N-[(1,3-benzothiazol-2-yl)sulfanyl]-2-nitrobenzene-1-sulfonamide
0.01 mM, 35.9% inhibition
-
N-[(azetidin-3-yl)methyl]-6-bromo-1H-indazol-4-amine
-
-
N-[(E)-(2-phenyl-3H-indol-3-yl)methylidene]hydroxylamine
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-3-methoxy-N-methylbenzamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-4-methoxy-N-methylbenzamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-N-(4-cyanophenyl)acetamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-N-methyl-4-nitrobenzamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-N-methylacetamide
-
-
N-[2-([[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]amino)-2-oxoethyl]-N-phenylacetamide
-
-
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]-2,2-dimethylpropanamide
0.01 mM, 72.35% inhibition
-
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]acetamide
0.01 mM, 57.47% inhibition
-
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]benzamide
0.01 mM, 65.72% inhibition
-
N-[2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]benzenesulfonamide
0.01 mM, 59.71% inhibition
-
N-[4-(2-phenylhydrazinesulfonyl)phenyl]acetamide
EC50 is over 0.010 mM
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(2-methylphenyl)urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(3-methylphenyl)urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(4-methoxyphenyl)urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-(4-methylphenyl)urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-phenylurea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-[4-(difluoromethoxy)phenyl]urea
-
-
N-[4-(2-tert-butylphenoxy)[1,1'-biphenyl]-3-yl]-N'-[4-(trifluoromethoxy)phenyl]urea
-
-
N-[4-[2-(2,4-difluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is over 0.010 mM
N-[4-[2-(3,4-dichlorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 350 nm
N-[4-[2-(3,5-dichlorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 508 nm
N-[4-[2-(3,5-difluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 2229 nm
N-[4-[2-(3-bromo-4-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 2494 nm
N-[4-[2-(3-bromophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 7563 nm
N-[4-[2-(3-chloro-4-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 2588 nm
N-[4-[2-(3-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is over 0.010 mM
N-[4-[2-(3-methylphenyl)hydrazinesulfonyl]benzoyl]glycine
EC50 is 571 nm
N-[4-[2-(3-methylphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 241 nm
N-[4-[2-(4-bromo-3-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 187 nm
N-[4-[2-(4-bromo-3-methylphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 130 nm
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-chlorophenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-cyanophenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-fluorophenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-methoxyphenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(3-methylphenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(4-chlorophenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(4-methoxyphenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-(4-methylphenyl)urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-butylurea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-cyclohexylurea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-[3-(1H-tetrazol-5-yl)phenyl]urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]-N'-[4-(1H-tetrazol-5-yl)phenyl]urea
-
-
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 85 nm
N-[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]butanamide
EC50 is 187 nm
N-[4-[2-(4-chloro-3-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 84 nm
N-[4-[2-(4-chlorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 142 nm
N-[4-[2-(4-cyanophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 1393 nm
N-[4-[2-(4-fluorophenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 609 nm
N-[4-[2-(4-methoxyphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is over 0.010 mM
N-[4-[2-(4-methylphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 1171 nm
N-[4-[2-(4-sulfamoylphenyl)hydrazinesulfonyl]phenyl]acetamide
EC50 is 3118 nm
N-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-2-(4-methylphenyl)acetamide
-
-
N-[4-[bis(2-methylpropyl)amino]-2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-3-yl]-N'-(4-methylphenyl)urea
-
-
N-[[(1S,2R)-2-aminocyclohexyl]methyl]-6-bromo-1H-indazol-4-amine
-
-
N-[[(1S,2S)-2-aminocyclohexyl]methyl]-6-bromo-1H-indazol-4-amine
-
-
N-[[(4-chlorophenyl)sulfanyl]methyl]-2-nitroaniline
-
N-[[(4-chlorophenyl)sulfanyl]methyl]-4-methylaniline
-
N-[[(4-chlorophenyl)sulfanyl]methyl]-4-nitroaniline
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-2-hydroxyacetamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-4-oxobutanamide
0.001 mM, 97% inhibition
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-(phenylacetyl)glycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-(phenylacetyl)glycinamide
0.001 mM, 62% inhibition
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(2-nitrophenyl)acetyl]glycinamide
0.001 mM, 67% inhibition
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(3-nitrophenyl)acetyl]glycinamide
0.001 mM, 65% inhibition
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-methyl-N2-[(4-nitrophenyl)acetyl]glycinamide
0.001 mM, 66% inhibition
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(2-chlorophenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(3,4-dihydroxyphenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(3-chlorophenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(3-hydroxyphenyl)acetyl]-N2-methylglycinamide
0.001 mM, 63% inhibition
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(4-chlorophenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(4-cyanophenyl)acetyl]-N2-methylglycinamide
-
-
N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]-N2-[(4-hydroxyphenyl)acetyl]-N2-methylglycinamide
-
-
N1-acetyl-N2-formyl-5-methoxykynurenine
-
N2-[(2S)-2-amino-2-phenylacetyl]-N-[[3-(4-bromophenyl)imidazo[2,1-b][1,3]thiazol-5-yl]methyl]glycinamide
-
-
NADH
-
0.1 mM, 51.3% inhibition
NaN3
-
10 mM, 33% inhibition of cleavage of D-tryptophan, 32% inhibition of cleavage of L-tryptophan
nitric oxide
-
nitric oxide can potentially inhibit isozyme IDO2 activity
noranhydroicaritin
non-competitive inhibitor
norharmane
NHM, noncompetitive versus L-Trp and competitive versus O2
NSC 401366
-
competitive with respect to tryptophan
palmatine
-
irreversible potent IDO-1 inhibitor
propan-2-yl 4-[([4-[2-(4-bromophenyl)hydrazinesulfonyl]phenyl]carbamoyl)amino]benzoate
-
-
prostaglandin (19R)-hydroxy-PGE2
-
-
prostaglandin 13,14-dihydro-15-oxo-PGE2
-
-
prostaglandin 15-oxo-PGE2
-
-
prostaglandin 15-oxo-PGF2alpha
-
-
prostaglandin 20-hydroxy PGE2
-
-
prostaglandin DELTA12-PGJ2
-
-
prostaglandin PGD2 ethanolamide
-
-
prostaglandin PGE2 ethanolamide
-
-
prostaglandin PGF2beta
-
-
S-(2-chlorophenyl) (4-chlorophenyl)carbamothioate
-
serotonin
-
1 mM, 36% inhibition of cleavage of D-tryptophan, 37% inhibition of cleavage of L-tryptophan
sodium 4-chlorobenzenesulfinate
-
-
sophoraflavanone B
non-competitive inhibitor
streptovaricin C
NSC19990
tenatoprazole
-
highly selective for IDO2 inhibition, no inhibition of IDO1 or tryptophan dioxygenase
tert-butyl 3-[[(6-bromo-1H-indazol-4-yl)amino]methyl]pyrrolidine-1-carboxylate
-
-
tert-butyl [2-(4,7-dioxo-5-phenyl-4,7-dihydro-1H-indol-3-yl)ethyl]carbamate
0.01 mM, 56.38% inhibition
-
tert-butyl [2-[4,7-dioxo-5-(pyridin-3-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 66.51% inhibition
-
tert-butyl [2-[4,7-dioxo-5-(pyridin-4-yl)-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 12.42% inhibition
-
tert-butyl [2-[5-(2-fluorophenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 67.30% inhibition
-
tert-butyl [2-[5-(2-methoxyphenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 63.23% inhibition
-
tert-butyl [2-[5-(4-fluorophenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 43.34% inhibition
-
tert-butyl [2-[5-(4-methoxyphenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 34.45% inhibition
-
tert-butyl [2-[5-(4-methylphenyl)-4,7-dioxo-4,7-dihydro-1H-indol-3-yl]ethyl]carbamate
0.01 mM, 25.52% inhibition
-
transforming growth factor-beta
-
inhibits expression in skin and synovial fibroblasts
-
xanthurenic acid
-
0.1 mM, 50.6% inhibition. 1 mM, 96.2% inhibition
[3-(4-bromobenzoyl)-1,2-oxazol-4-yl](naphthalen-2-yl)methanone
0.01 mM, 28.4% inhibition
-
[4-(1,4-dioxido-1,2,4-benzotriazin-3-yl)aminobutyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
[4-(1-oxido-1,2,4-benzotriazin-3-yl)aminobutyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
[4-[2-(4-bromophenyl)hydrazinesulfonyl]phenoxy]acetic acid
EC50 is 152 nm
[5-(1,4-dioxido-1,2,4-benzotriazin-3-yl)aminopentyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
[5-(1-oxido-1,2,4-benzotriazin-3-yl)aminopentyl]-(2S)-N-tert-butoxycarbonyl-2-amino-(1-methyl-indole-3-yl)propanamide
-
-
1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol
-
1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol
-
-
1-L-methyltryptophan
-
-
1-methyl-D-tryptophan
-
IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan
1-methyl-D-tryptophan
-
-
1-methyl-D-tryptophan
-
competitive inhibitor
1-methyl-D-tryptophan
-
the isomer is more effective in inhibiting IDO than 1-methyl-L-tryptophan
1-methyl-D-tryptophan
-
selective inhibition of IDO2, 1DMT is not efficacious in a tumor model on an IDO1-/- background
1-methyl-D-tryptophan
competitive inhibition of IDO2, antitumour activity, selectivity of 1-methyltryptophan inhibition of IDO1 and IDO2
1-methyl-D-tryptophan
IDO inhibitor with selectivity for IDO2
1-methyl-D-tryptophan
-
-
1-methyl-D-tryptophan
-
poor non-competitive inhibitor of both IDO1 and IDO2 activity
1-methyl-D-tryptophan
-
-
1-methyl-D-tryptophan
-
the isomer is more effective in inhibiting IDO than 1-methyl-L-tryptophan
1-methyl-D-tryptophan
-
-
1-methyl-DL-Trp
-
-
1-methyl-DL-tryptophan
-
competitive inhibition with L-tryptophan, 2 mM, 70% inhibition
1-methyl-DL-tryptophan
-
-
1-methyl-DL-tryptophan
-
1 mM, 26% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
1-methyl-DL-tryptophan
-
-
1-methyl-DL-tryptophan
-
competitive inhibitor
1-methyl-DL-tryptophan
-
pharmacologic inhibition of indoleamine 2,3-dioxygenase skews cytokine responses of invariant natural killer T cells towards a Th1 profile
1-methyl-DL-tryptophan
-
-
1-methyl-L-tryptophan
-
1-methyl-L-tryptophan
-
-
1-methyl-L-tryptophan
-
substrate inhibition, 1-methyl-D-tryptophan exhibits no inhibitory effect
1-methyl-L-tryptophan
-
competitive inhibitor
1-methyl-L-tryptophan
-
the isomer is less effective in inhibiting IDO than 1-methyl-D-tryptophan
1-methyl-L-tryptophan
-
-
1-methyl-L-tryptophan
-
better inhibitor of IDO2 enzymatic activity than 1DMT in both cell-free and cellular assays
1-methyl-L-tryptophan
competitive inhibition of IDO1, antitumour activity, selectivity of 1-methyl L-tryptophan inhibition of IDO1 and IDO2; competitive inhibition of IDO2, antitumour activity, selectivity of 1-methyltryptophan inhibition of IDO1 and IDO2
1-methyl-L-tryptophan
competitive versus L-Trp and noncompetitive versus O2. When 1-Me-L-Trp is the only indoleamine in the reaction mixture, it is a very slow substrate for hIDO1
1-methyl-L-tryptophan
-
-
1-methyl-L-tryptophan
-
-
1-methyl-L-tryptophan
-
poor competitive inhibitor of isozyme IDO1
1-methyl-L-tryptophan
-
the isomer is less effective in inhibiting IDO than 1-methyl-D-tryptophan
1-methyl-L-tryptophan
-
better inhibitor of IDO2 enzymatic activity than 1DMT in both cell-free and cellular assays
1-methyl-tryptophan
-
-
1-methyl-tryptophan
-
competitive
1-methyl-tryptophan
non-competitive inhibitor
1-Methyltryptophan
-
2 mM, 70% inhibition; competitive
1-Methyltryptophan
-
competitive
1-Methyltryptophan
-
treatment of pregnant mice result in rapid T-cell-induces rejection of allogeneic concepti
2-(1H-imidazol-4-yl)phenol
-
2-(1H-imidazol-4-yl)phenol
-
-
2-(1H-imidazol-4-yl)phenol
-
3-(1H-1,2,3-triazol-5-yl)pyridine
-
3-(1H-1,2,3-triazol-5-yl)pyridine
-
-
3-hydroxykynurenine
-
0.1 mM, 89.8% inhibition
3-hydroxykynurenine
-
0.1 mM, weak inhibition amounting to about 30%
4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
-
4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
-
4-amino-N-(3-chloro-4-fluorophenyl)-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide
i.e. Incyte-5l
4-phenyl-1,3-thiazol-2-amine
-
4-phenyl-1,3-thiazol-2-amine
0.1 mM, 13% inhibition
4-phenylimidazole
-
-
4-phenylimidazole
weak noncompetitive inhibitor of IDO
4-phenylimidazole
-
an IDO1 inhibitor
4-phenylimidazole
-
heme ligand, non competitive, 0.1 M potassium phosphate buffer (pH 5.5-8), 0.1 M Tris-HCl buffer (pH 7.5-8), 25°C
5-hydroxy-L-tryptophan
-
1 mM, 12% inhibition relative to L-tryptophan, 50 mM potassium phosphate, pH 6.5, 10 mM ascorbic acid, 0.01 mM methylene blue, 0.1 mg catalase, 37°C, 10 min
5-hydroxy-L-tryptophan
-
0.1 mM, 40% inhibition of cleavage of D-tryptophan, 53% inhibition of cleavage of L-tryptophan
5-phenyl-1H-1,2,3-triazole
-
5-phenyl-1H-1,2,3-triazole
-
-
annulin B
-
-
brassinin
-
-
CN-
-
0.4 mM, 86% inhibition
CN-
-
9.6 mM, 50% inhibition
CN-
-
5 mM, 98% inhibition
CO
-
20% with 80% air, 78% inhibition
CO
-
negatively cooperative
CO
-
reversed by illumination
cyanide
-
prebinding of cyanide to the enzyme facilitates L-Trp binding by 22fold but retards its dissociation by 2fold, indicating that cyanide binding to the heme iron introduces structural changes to the protein matrix allowing faster access of the substrate to the active site and slower dissociation from it. Prebinding of L-Trp to the enzyme retards cyanide binding by about 13fold
cyanide
-
inhibits the dioxygenase activity
cyanide
-
heme ligand, competitive for the ferric enzyme
D-Trp
-
no inhibition
D-tryptophan
low inhibition
dexamethasone
-
inhibits IDO activity in brain and lung after systemic pokeweed mitogen administration and brains of mice suffering from malaria
diethyldithiocarbamate
-
-
diethyldithiocarbamate
-
5 mM, markedly enhances activity
diethyldithiocarbamate
-
-
DL-4-fluorotryptophan
-
-
DL-4-fluorotryptophan
-
-
DL-4-methyltryptophan
-
-
DL-4-methyltryptophan
-
-
DL-5-fluorotryptophan
-
-
DL-5-fluorotryptophan
-
-
DL-5-fluorotryptophan
-
-
DL-5-Methyltryptophan
-
-
DL-5-Methyltryptophan
-
-
DL-5-Methyltryptophan
-
-
epacadostat
pH and temperature not specified in the publication
-
exiguamine A
-
inihibor isolated from the marine sponge Neopetrosia exigua
H2O2
at high concentrations
H2O2
-
inhibits the dioxygenase activity in a manner abrogated by L-Trp. Physiological peroxidase substrates, ascorbate or tyrosine, enhanced rIDO-mediated H2O2 consumption and attenuated H2O2-induced protein oxidation and dioxygenase inhibition. H2O2 alters the heme active site of recombinant IDO
H2O2
-
inactivated by H2O formed by ascorbic acid in presence of methylen blue
hydroxylamine
-
-
indole
-
1 mM, 44% inhibition
indole
-
lowers Km value for D-tryptophan by 60% at pH 7, lowers Vmax by 12-24%, at 1 mM lowers activity by 13%
Indolepropionic acid
-
1 mM, 31% inhibition
KCN
-
0.01 mM, 39% inhibition of cleavage of D-tryptophan, 48% inhibition of cleavage of L-tryptophan
L-5-hydroxytryptophan
-
-
L-5-hydroxytryptophan
-
-
L-tryptophan
-
substrate inhibition at 0.14 mM and greater
L-tryptophan
-
substrate inhibition
L-tryptophan
-
substrate inhibition (above 0.05 mM)
L-tryptophan
-
substrate inhibition at concentrations above 0.04 mM
L-tryptophan
-
substrate inhibition of IDO1, not of IDO2
L-tryptophan
-
substrate inhibition
menadione
menadione effectively inhibits L-Trp oxidation from reactions supported with ascorbaic acid/methylene blue
N3-
-
2 mM, 22% inhibition
N3-
-
5 mM, 5% inhibition
NH2OH
-
2 mM, 54% inhibition
NO
-
-
NO
can inhibit hIDO by directly binding to the heme iron
NO
-
inhibits activity reversibly by binding to the active site heme to trap the enzyme as an inactive nitrosyl-FeII enzyme adduct with Trp bound and O2 displaced. Reversible inhibition by NO may represent an important mechanism in controlling the immune regulatory actions of IDO
NO
-
inhibits the transcription of IDO in murine macrophages
norharman
-
2 mM, 98% inhibition, uncompetitive; uncompetitive inhibition, 2 mM, 98% inhibition
norharman
-
non competitive, competitive for the ferric enzyme, 0.1 M potassium phosphate buffer (pH 5.5-8), 0.1 M Tris-HCl buffer (pH 7.5-8), 25°C
norharman
-
can bind to the ferric and ferrous enzyme to from a quarternary complex
O2
-
-
O2
inhibition of mutant forms H55A and H55S at high concentrations
Sodium azide
-
1 mM causes 20% inhibition
Superoxide dismutase
-
80-98% inhibition
-
Superoxide dismutase
-
-
-
Superoxide dismutase
-
can be inhibited by diethyldithiocarbamate
-
Tiron
-
10 mM, 2% inhibition of cleavage of D-tryptophan, 6% inhibition of cleavage of L-tryptophan
Tiron
-
1 mM causes 40% inhibition
tryptamine
-
1 mM, 23% inhibition
tryptamine
-
0.1 mM, 16% inhibition of cleavage of D-tryptophan, 11% inhibition of cleavage of L-tryptophan
additional information
-
synthesis and inhibition study of tryptophan 2,3-dioxygenase with 3,8-substituted 5H-indeno[1,2-c]pyridazin-5-one derivatives, overview. No inhibition by 7b
-
additional information
-
no inhibition by D-5-hydroxytryptophan
-
additional information
-
not inhibited by indo-3-acetamide, beta-indoylacetonitrile snd 3-beta-indoleacrylic acid
-
additional information
-
not inhibited by 6-nitro-D-tryptophan and indole-nitrogen substituted analogues of trytophan
-
additional information
review article sumarizing data of many inhibitors of indoleamine 2,3-dioxygenase
-
additional information
-
sodium butyrate does not inhibit the activity of IDO
-
additional information
-
the traditional Chinese medicinal prescription Oren-gedoku-to significantly inhibits recombinant human IDO-1 activity in vitro
-
additional information
not inhibited by 1-methyl-D-tryptophan
-
additional information
F5H5G0
no inhibition by phenylthiohydantoin-Trp; no inhibition by phenylthiohydantoin-Trp
-
additional information
no inhibition by phenylthiohydantoin-Trp; no inhibition by phenylthiohydantoin-Trp
-
additional information
-
no inhibition by phenylthiohydantoin-Trp; no inhibition by phenylthiohydantoin-Trp
-
additional information
-
structure-activity relationship and enzyme kinetics of 4-aryl-1H-1,2,3-triazoles as indoleamine 2,3-dioxygenase inhibitors, molecular docking studies, overview. An electron-withdrawing group with low steric hindrance near the NH group of triazoles is necessary for the IDO inhibition. No inhibition by 5-(4-methylphenyl)-1H-1,2,3-triazole, methyl 4-(1H-1,2,3-triazol-5-yl)benzoate, 4-bromo-5-phenyl-1H-1,2,3-triazole, 4-chloro-5-phenyl-1H-1,2,3-triazole, 1H-benzotriazol-1-ol, and 5-(4-bromophenyl)-1H-tetrazole
-
additional information
-
the dioxygenase enzyme activity is inhibited by free radical scavengers. Protection of the dioxygenase enzyme function by L-Trp coincides with its oxidation into oxindolylalanine and kynurenine and the formation of a compound II-type ferryl-oxo heme
-
additional information
no inhibition of IDO1 by 1-methy-D-tryptophan; no inhibition of IDO1 by L-tryptophan
-
additional information
no inhibition of IDO1 by 1-methy-D-tryptophan; no inhibition of IDO1 by L-tryptophan
-
additional information
-
no inhibition of IDO1 by 1-methy-D-tryptophan; no inhibition of IDO1 by L-tryptophan
-
additional information
structure-activity relationships of phenyl benzenesulfonylhydrazides as indoleamine 2,3-dioxygenase inhibitors, overview. Coupling reactions between various benzenesulfonyl chlorides and phenylhydrazides are utilized to synthesize the sulfonylhydrazides bearing various substituents. EC50 values, overview
-
additional information
NCI library inhibitor screening, and analysis of active site-inhibitor interactions, overview. Importance of Ser167 and Cys129 residues in the IDO1 active site for inhibitor binding. Structure-activity relationship studies propose substituents interacting with Ser167 on four investigated IDO1 inhibitors. Three of these four Ser167 interactions associate with an increased IDO1 inhibition and are correctly predicted by molecular docking supporting Ser167 as an important mediator of potency for IDO1 inhibitors. IC50 values in presence or absence of Tween 20 and reduced glutathione
-
additional information
identification of substituted naphthotriazolediones as tryptophan 2,3-dioxygenase (TDO) inhibitors through structure-based virtual screening, homology modeling and virtual screening, ligand docking analysis, overview
-
additional information
suppressive effect of plant extracts or phytochemicals on IDO1 induction and activity. The methanol extracts of Myoga flower buds, which are traditional Japanese foods, and labdane-type diterpene galanal derived from Myoga flowers significantly suppress IDO1 activity
-
additional information
-
suppressive effect of plant extracts or phytochemicals on IDO1 induction and activity. The methanol extracts of Myoga flower buds, which are traditional Japanese foods, and labdane-type diterpene galanal derived from Myoga flowers significantly suppress IDO1 activity
-
additional information
-
inhibition of indoleamine 2,3-dioxygenase activity by fatty acids, eicosanoids and prostaglandins, structure-function-analysis, overview. No inhibition by (6Z,9Z,12Z)-octadecatrienoic and (6Z,9Z,12Z,15Z)-octadecatetraenoic
-
additional information
a high throughput virtual screening cascade protocol is validated and can be employed in discovery of IDO1 inhibitors
-
additional information
1H-indazole-4-amines inhibit both human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) by a mechanism involving direct coordination with the heme ferrous and ferric states
-
additional information
-
1H-indazole-4-amines inhibit both human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) by a mechanism involving direct coordination with the heme ferrous and ferric states
-
additional information
-
inhibition of indoleamine 2,3-dioxygenase may be developed as an anticancer immunotherapeutic strategy
-
additional information
-
not inhibited by superoxide dismutase
-
additional information
-
review article sumarizing data of many inhibitors of indoleamine 2,3-dioxygenase
-
additional information
-
3-indoleethanol and indole affect the L-tryptophan affinity of the ferrous enzyme, indole enhances affinity of enzyme for cyanide and azide and norharman, L-tryptophan lowers norharman affinity for the ferrous dioxygenase
-
additional information
-
not inhibited by catalase and D-tryptophan
-
additional information
-
catabolite repression of the pathway by glucose and glutamate, arginine does not cause repression, no inhibition by D-tryptophan
-
additional information
-
no inhibition by D-5-hydroxytryptophan
-